An overview of the contemporary diagnosis and management approaches for anaplastic thyroid carcinoma  

作　　者：Shu-Yue Zhou Lian-Xiang Luo 

机构地区：[1]The First Clinical College,Guangdong Medical University,Zhanjiang 524023,Guangdong Province,China [2]The Marine Biomedical Research Institute,Guangdong Medical University,Zhanjiang 524000,Guangdong Province,China

出　　处：《World Journal of Clinical Oncology》2024年第6期674-676,共3页世界临床肿瘤学杂志（英文版）

摘　　要：Thyroid carcinoma is a complex disease with several types,the most common being well-differentiated and undifferentiated.The latter,“undifferentiated carcinoma”,also known as anaplastic thyroid carcinoma(ATC),is a highly aggr-essive malignant tumor accounting for less than 0.2%of all thyroid carcinomas and carries a poor prognosis with a median survival of 5 months.BRAF gene mutations are the most common molecular factor associated with this type of thyroid carcinoma.Recent advances in targeted biological agents,immuno-therapy,stem cell therapy,nanotechnology,the dabrafenib/trametinib com-bination therapy,immune checkpoint inhibitors(ICI)and artificial intelligence offer novel treatment options.The combination therapy of dabrafenib and tra-metinib is the current standard treatment for patients with BRAF-V600E gene mutations.Besides,the dabrafenib/trametinib combination therapy,ICI,used alone or in combination with targeted therapies have raised some hopes for improving the prognosis of this deadly disease.Younger age,earlier tumor stage and radiotherapy are all prognostic factors for improved outcomes.Ultimately,therapeutic regimens should be tailored to the individual patient based on surveillance and epidemiological data,and a multidisciplinary approach is ess-ential.

关 键 词：Thyroid diseases Thyroid cancers Anaplastic carcinoma Undifferentiated carcinoma Neck mass Aggressive malignancies 

分 类 号：R736.1[医药卫生—肿瘤]